FY22 House Appropriations Bill Includes $20M for NF Research

Author: NF Network, Breanna Bronowski-Stutsman

Published On: 07/28/2021

While we may not have been walking the Halls of Congress in February, nearly 80 advocates participating in the Neurofibromatosis Network Advocacy Program were still hard at work sharing your stories with your representatives and educating Congress on the importance of federal funding for NF research. Our advocates spoke with, spoke out, and spoke for the thousands living with neurofibromatosis, serving as one voice for the NF community.

Upon completing our Virtual Hill Visits, we asked you to write to your members of Congress and request they sign on to the House and Senate "Dear Colleague" letters. Your requests asked for support of continued federal funding for NF research, and with your help, we had 134 House signatures and 22 Senate signatures on these letters! See below the representatives who signed on:

Thanks to your advocacy efforts, we are pleased to announce that the House Appropriations Committee has included $20 million for the Neurofibromatosis Research Program (NFRP) in their Fiscal Year 2022 Defense spending bill! The next step in the process will occur when the House Appropriations Committee considers the bill on Tuesday, July 13. While the bill will then have to pass in the House of Representatives, be considered by the Senate Appropriations Committee and the full Senate, and be signed by the President before it becomes law, we are one step closer to securing this funding for critical NF research! We will continue to update you as the legislation makes its way through Congress.

We THANK YOU for your continued advocacy efforts and your support of the NF Network Advocacy Program. With your unwavering support, we are able to continue educating congressional offices on the importance of these federal research dollars for NF research and help accelerate the search for treatments and a cure to end neurofibromatosis.

To learn more about the NF Network Advocacy Program, please click here.